re: AUPH - Aurinia Pharmaceuticals

quote:

---

Ultimately, where do you see this stock going? What’s its ceiling?

---

Since nothing has gone wrong, it has no ceiling.
Think about what's on the line with two of their biggest needs.

1) First and foremost, Lupus Nephritis. This market is estimated at 3-5.5 Billion dollars by 2023
Aurinia will likely own the ENTIRE LN market. They are THE hope for people with this disease.

2) Dry Eye Syndrome. They have already begun the task of unseating Restasis in the DES market. Restasis sales rake in about 2 billion annually for Allergan. There is good reason to believe that AUPH's VOS can prove more effective than Restasis, and we'll know more about that as soon as mid summer.
Aurinia will take a significant share of the Dry Eye market

3) Aurinia is also at work on some other lesser known Kidney diseases for which data will again be released this year.

If all goes well, AUPH will be a 5 billion dollar company in 2-3 years.
What does that look like? $60/share
The question is, will they sell out early for an offer of 3 billion or $30/share?